Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
about
Targeting the insulin growth factor receptor 1Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsRepurposing metformin for cancer treatment: current clinical studiesMetformin therapy and risk of cancer in patients with type 2 diabetes: systematic reviewMetformin in obesity, cancer and aging: addressing controversiesLifestyle factors associated with type 2 diabetes and use of different glucose-lowering drugs: cross-sectional studyLeucine signaling in the pathogenesis of type 2 diabetes and obesityAMPK activation--protean potential for boosting healthspan.Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines.Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapyAre metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?The insulin receptor: a new target for cancer therapy.Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary TumorigenesisDietary intervention in acne: Attenuation of increased mTORC1 signaling promoted by Western diet.Metformin Is Associated with a Favorable Outcome in Diabetic Patients with Cervical Lymph Node Metastasis of Differentiated Thyroid CancerPre-diagnosis blood glucose and prognosis in women with breast cancer.Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer.Diabetes, metformin, and breast cancer in postmenopausal womenContextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells.Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.Does use of metformin protect against cancer in Type 2 diabetes mellitus?Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature.Pharmacological treatment of diabetes in older people.Antihyperglycaemic therapies and cancer risk.Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance.Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer.Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer.Metformin: A Bridge between Diabetes and Prostate Cancer.Role of metformin on base excision repair pathway in p53 wild-type H2009 and HepG2 cancer cells.Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma.Metformin targets Mitochondrial Glycerophosphate Dehydrogenase (mGPDH) to control Rate of Oxidative Phosphorylation and growth of thyroid cancer in vitro and in vivo.Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment
P2860
Q24633750-5F0AEE7D-75A6-46F2-B1A8-1570EA503F42Q26750845-F085698C-6E24-4308-BC93-D31CF26ECAAEQ26752651-6432077F-CBEA-4AB7-AFE9-0B55F252F653Q26850912-16BC84BE-F8F7-4A6A-9520-E081EE17EB5FQ28480735-DB02AAD8-B1DE-4839-A2F0-D512A9B928B8Q28544717-20C961F7-8DC1-4432-8A4E-D1C8E8681A2EQ29543116-CB2930E5-69CC-4618-B16E-BA1BA614A9A3Q33689169-46E8FA39-EA25-408E-9DD5-9D37E6E5F53AQ33702357-7515484E-D0F8-4BCE-9E2F-57CBF6DFA76FQ34135248-1AC7FBED-FE1C-4DCF-9B98-27FA837347ADQ35149589-2787441E-07A3-427E-B649-4BE63F55E1C3Q35909683-161AD928-9613-4520-AD23-238F80DF40D1Q35972002-603A8ACE-5176-4FC5-A6B3-7C8283EFFEE2Q36078840-6610008D-9DC8-489E-9E26-2640F350D42EQ36130010-2957D562-17AA-4E7D-A1D5-15D9ADDBB7B9Q36261224-66B621C6-5808-41FE-A6C6-C7BB84C8998AQ36769486-EEE0A354-9CF0-4700-B973-1C2286254209Q37290538-4B0DEDEC-4B5B-4800-A47B-372D1B04E7ECQ37303867-E5823C62-5BB9-4A33-B7CB-48C6503AD734Q37471852-4260B837-4D70-4C88-A36D-556AA40239CDQ38000089-09ED0DEF-4E48-453D-98D5-169F44F3038AQ38001521-EEDAF1F4-0796-4591-9A7B-DFD2E2CAEE75Q38226775-FEB5A48A-FF8B-4744-AAE8-6615D0741C66Q38235153-1F3873DE-ED67-4D5E-B219-45320E197552Q38250719-62FC53BE-CE00-4DCB-AF57-8FB6AB5937A8Q38374279-56150367-5144-4562-ABC3-B3E9CA57A0A8Q39043221-F46E5576-7427-4ECD-A973-84677C699C29Q39648521-27410883-88E9-4091-BA8A-530E042CCF65Q41108020-732426C3-A71E-413B-BB66-419D36FB213BQ41435904-1A014946-F400-45EC-A1E4-200B4346E9E7Q42117918-AE51BA93-FE49-4B20-9901-916C273D7DDDQ42700292-8A553135-6EB1-4D7D-B548-52E4B61B25F5Q46252237-D6DB320E-893F-4998-A8B7-3F9C13A0A3C2Q46976979-6C9D6A8F-88A2-43E7-9E28-FE4E5A929339Q52565556-61B01D24-89C7-4E93-AB0D-28DAB44B1AB1Q52757920-6E46914A-7BC3-4B68-8356-C5709D9A1D9CQ57734588-560EFE45-E6CD-4317-86D2-620993A33F45
P2860
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@en
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@nl
type
label
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@en
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@nl
prefLabel
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@en
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@nl
P2093
P2860
P1476
Cancer mortality reduction and ...... y in type 2 diabetic patients.
@en
P2093
P2860
P356
10.1111/J.1463-1326.2011.01480.X
P577
2011-11-21T00:00:00Z